Christy Oliger brings nearly 30 years of strategic and operational experience in the biopharmaceutical industry. She built her career at Schering Plough and Genentech where she held varied roles in commercial and business unit leadership, as well as global R&D portfolio and project management. Most recently, Christy served as Senior Vice President, Oncology Business Unit Head at Genentech managing a portfolio of 15 products and ~$13B US revenue. She has also been responsible for overseeing the successful launches of Ocrevus for Multiple Sclerosis, Hemlibra for Hemophilia and Evrysdi for Spinal Muscular Atrophy. Christy currently sits on the boards of Karyopharm Therapeutics, Reata Pharmaceuticals and Sierra Oncology. She completed her undergraduate work in Economics at University of California, Santa Barbara.